Ibuvit D3 Baby (Colecalciferol)

Colecalciferol is converted first to 25‑hydroxyvitamin D in the liver and then to the active hormone 1,25‑dihydroxyvitamin D in the kidneys. The active form binds to vitamin D receptors, increasing the expression of calcium‑binding proteins in the intestine, which enhances calcium and phosphate absorption essential for bone formation.

The appropriate dose of Ibuvit D3 Baby is determined by a qualified healthcare professional based on the infant’s age, weight, and serum vitamin D level. Parents should follow the prescriber’s instructions and not adjust the dose without medical advice.

Ibuvit D3 Baby is formulated for infants and is not intended for use by pregnant or breastfeeding women. Women who are pregnant or nursing should consult their healthcare provider for appropriate vitamin D supplementation that matches adult dosing guidelines.

To order Ibuvit D3 Baby, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ibuvit D3 Baby delivers colecalciferol, the same active form found in most vitamin D3 preparations. Compared with vitamin D2 (ergocalciferol), colecalciferol has higher potency and longer duration of action, making it the preferred choice for infant supplementation when formulated to appropriate pediatric dosing.

Store Ibuvit D3 Baby at temperatures below 25 °C, in its original container, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to extreme heat or humidity, which could degrade the vitamin content.

Ibuvit D3 Baby is taken orally, typically as a few drops placed directly into the infant’s mouth or mixed with a small amount of food or liquid, as directed by the prescriber. The exact administration technique and volume should follow the healthcare professional’s guidance.

The most serious risk is hypercalcemia, which can occur if the supplement is taken in excess. Symptoms include lethargy, vomiting, dehydration, and in severe cases, cardiac arrhythmias or kidney damage. Regular monitoring of serum calcium and vitamin D levels helps mitigate this risk.

Infants with known hypersensitivity to colecalciferol or any excipients in the formulation should avoid the product. Additionally, infants with conditions that cause elevated calcium levels, such as hyperparathyroidism or certain granulomatous diseases, should not receive this supplement without medical supervision.